Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019
- PMID: 32709434
- DOI: 10.1016/j.vaccine.2020.07.007
Monitoring the safety of high-dose, trivalent inactivated influenza vaccine in the vaccine adverse event reporting system (VAERS), 2011 - 2019
Abstract
Background: On 12/23/2009 a new high-dose trivalent inactivated influenza vaccine (IIV3-HD) was licensed for adults aged ≥65 years. We assessed the post-licensure safety data for IIV3-HD in the Vaccine Adverse Event Reporting System (VAERS) during 2011-2019.
Methods: We searched VAERS for reports after IIV3-HD during 1/1/2011-06/30/2019 in persons aged ≥65 years. Medical records were reviewed for all death reports and for certain pre-specified conditions (e.g. Guillain Barré Syndrome [GBS], anaphylaxis). We also reviewed certain groups who received IIV3-HD erroneously (e.g. pregnant women, children). Empirical Bayesian data mining was used to identify disproportional reporting.
Results: VAERS received 12,320 reports after IIV3-HD;723 reports (5.9%) were serious. The most common adverse events (AEs) among serious reports were pyrexia (30.2%), asthenia (28.9%), and dyspnea (24.9%), and among non-serious reports were injection site erythema (16.8%), pain in extremity (15.8%), and injection site pain (14.2%). Among 55 death reports, the most common causes of death were diseases of the circulatory system (n = 23;41.8%). Based on medical record review, there were 61 reports of GBS and 13 of anaphylaxis. There were 13 reports of pregnant-women who inadvertently received IIV3-HD; three reports described arm pain or local reactions, and 10 did not report any AE. Among 59 reports of children who erroneously received IIV3-HD, 31 experienced an AE (most commonly injection site or constitutional reactions) and the remaining 28 reports did not describe any AE.
Conclusions: Post-licensure safety data of IIV3-HD during 9 influenza seasons revealed no new or unexpected safety concerns among individuals ≥65 years. Inadvertent administration of IIV3-HD to children or pregnant women was observed, although with no serious AEs reported. Training and education of providers in vaccine recommendations and groups for whom the vaccine is indicated may help in preventing these vaccine administration errors. This review provides baseline information for future monitoring of the quadrivalent-high-dose influenza vaccine.
Keywords: Epidemiology; High-dose inactivated influenza vaccine; Post-licensure surveillance; Vaccine safety.
Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.Vaccine. 2023 Mar 10;41(11):1859-1863. doi: 10.1016/j.vaccine.2022.12.069. Epub 2023 Jan 9. Vaccine. 2023. PMID: 36669964 Free PMC article. Review.
-
Post-licensure surveillance of trivalent adjuvanted influenza vaccine (aIIV3; Fluad), Vaccine Adverse Event Reporting System (VAERS), United States, July 2016-June 2018.Vaccine. 2019 Mar 7;37(11):1516-1520. doi: 10.1016/j.vaccine.2019.01.052. Epub 2019 Feb 7. Vaccine. 2019. PMID: 30739795
-
Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Vaccine. 2016. PMID: 27015735 Free PMC article. Review.
-
Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22. Vaccine. 2014. PMID: 25258101
-
Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.Clin Infect Dis. 2012 Jun;54(11):1608-14. doi: 10.1093/cid/cis256. Epub 2012 Mar 22. Clin Infect Dis. 2012. PMID: 22441652
Cited by
-
Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021-2022.Can Commun Dis Rep. 2024 Jan 1;50(1-2):16-24. doi: 10.14745/ccdr.v50i12a02. eCollection 2024 Jan 1. Can Commun Dis Rep. 2024. PMID: 38655243 Free PMC article.
-
Stroke Risk After COVID-19 Bivalent Vaccination Among US Older Adults.JAMA. 2024 Mar 19;331(11):938-950. doi: 10.1001/jama.2024.1059. JAMA. 2024. PMID: 38502075
-
[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra® 2.0].J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec. J Prev Med Hyg. 2023. PMID: 37034835 Free PMC article. Italian. No abstract available.
-
A Mobile App Leveraging Citizenship Engagement to Perform Anonymized Longitudinal Studies in the Context of COVID-19 Adverse Drug Reaction Monitoring: Development and Usability Study.JMIR Hum Factors. 2022 Nov 4;9(4):e38701. doi: 10.2196/38701. JMIR Hum Factors. 2022. PMID: 35930561 Free PMC article.
-
Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.Vaccine. 2022 May 20;40(23):3174-3181. doi: 10.1016/j.vaccine.2022.04.046. Epub 2022 Apr 18. Vaccine. 2022. PMID: 35465979 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical